{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T06:39:10Z","timestamp":1778395150769,"version":"3.51.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"National Health and Medical Research Council of Australia","award":["Program grant 402761 and"],"award-info":[{"award-number":["Program grant 402761 and"]}]},{"name":"National Health and Medical Research Council of Australia","award":["APP1093017"],"award-info":[{"award-number":["APP1093017"]}]},{"name":"National Health and Medical Research Council of Australia","award":["Career Development Fellowship #1147843"],"award-info":[{"award-number":["Career Development Fellowship #1147843"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["NIH RO1 Grant CA83115"],"award-info":[{"award-number":["NIH RO1 Grant CA83115"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Highland Island Enterprise","award":["HMS9353763"],"award-info":[{"award-number":["HMS9353763"]}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"crossref","award":["Senior Principal Research Fellowship"],"award-info":[{"award-number":["Senior Principal Research Fellowship"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Familial Cancer"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s10689-020-00209-x","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T05:05:32Z","timestamp":1601355932000},"page":"231-239","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["FRAMe: Familial Risk Assessment of Melanoma\u2014a risk prediction tool to guide CDKN2A germline mutation testing in Australian familial melanoma"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4614-8399","authenticated-orcid":false,"given":"Elizabeth A.","family":"Holland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5092-5544","authenticated-orcid":false,"given":"Serigne","family":"Lo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0105-4281","authenticated-orcid":false,"given":"Blake","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0517-2939","authenticated-orcid":false,"given":"Helen","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5331-6370","authenticated-orcid":false,"given":"Anne E.","family":"Cust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2702-522X","authenticated-orcid":false,"given":"Jane M.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Drummond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4760-1033","authenticated-orcid":false,"given":"Nicholas K.","family":"Hayward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5336-0454","authenticated-orcid":false,"given":"Antonia L.","family":"Pritchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1301-405X","authenticated-orcid":false,"given":"Graham J.","family":"Mann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,29]]},"reference":[{"key":"209_CR1","unstructured":"Australian Institute of Health and Welfare, Cancer in Australia 2019. 2019: Canberra:AIHW."},{"issue":"2","key":"209_CR2","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/pcmr.12333","volume":"28","author":"LG Aoude","year":"2015","unstructured":"Aoude LG et al (2015) Genetics of familial melanoma: 20 years after CDKN2A. Pigment Cell Melanoma Res 28(2):148\u2013160","journal-title":"Pigment Cell Melanoma Res"},{"issue":"15","key":"209_CR3","first-page":"210","volume":"3","author":"M Potrony","year":"2015","unstructured":"Potrony M et al (2015) Update in genetic susceptibility in melanoma. Ann Transl Med 3(15):210","journal-title":"Ann Transl Med"},{"issue":"1","key":"209_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jmedgenet-2015-103150","volume":"53","author":"J Read","year":"2016","unstructured":"Read J, Wadt KA, Hayward NK (2016) Melanoma genetics. J Med Genet 53(1):1\u201314","journal-title":"J Med Genet"},{"issue":"7","key":"209_CR5","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1038\/jid.2012.75","volume":"132","author":"MH Law","year":"2012","unstructured":"Law MH, Macgregor S, Hayward NK (2012) Melanoma genetics: recent findings take us beyond well-traveled pathways. J Invest Dermatol 132(7):1763\u20131774","journal-title":"J Invest Dermatol"},{"issue":"1","key":"209_CR6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1897-4287-12-20","volume":"12","author":"M Harland","year":"2014","unstructured":"Harland M et al (2014) Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom. Hered Cancer Clin Pract 12(1):20","journal-title":"Hered Cancer Clin Pract"},{"issue":"2","key":"209_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1136\/jmg.2006.043802","volume":"44","author":"AM Goldstein","year":"2007","unstructured":"Goldstein AM et al (2007) Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 44(2):99\u2013106","journal-title":"J Med Genet"},{"issue":"4","key":"209_CR8","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1136\/jmg.2010.086538","volume":"48","author":"AE Cust","year":"2011","unstructured":"Cust AE et al (2011) Melanoma risk for CDKN2A mutation carriers who are relatives of population-based case carriers in Australia and the UK. J Med Genet 48(4):266\u2013272","journal-title":"J Med Genet"},{"issue":"12","key":"209_CR9","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/jnci\/94.12.894","volume":"94","author":"DT Bishop","year":"2002","unstructured":"Bishop DT et al (2002) Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 94(12):894\u2013903","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"209_CR10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40258-017-0368-0","volume":"16","author":"CG Watts","year":"2018","unstructured":"Watts CG et al (2018) A national budget impact analysis of a specialised surveillance programme for individuals at very high risk of melanoma in Australia. Appl Health Econ Health Policy 16(2):235\u2013242","journal-title":"Appl Health Econ Health Policy"},{"issue":"1","key":"209_CR11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1200\/JCO.2016.68.4308","volume":"35","author":"CG Watts","year":"2017","unstructured":"Watts CG et al (2017) Cost-Effectiveness of skin surveillance through a specialized clinic for patients at high risk of melanoma. J Clin Oncol 35(1):63\u201371","journal-title":"J Clin Oncol"},{"issue":"1","key":"209_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/bjd.13403","volume":"172","author":"CG Watts","year":"2015","unstructured":"Watts CG et al (2015) Clinical practice guidelines for identification, screening and follow-up of individuals at high risk of primary cutaneous melanoma: a systematic review. Br J Dermatol 172(1):33\u201347","journal-title":"Br J Dermatol"},{"issue":"4","key":"209_CR13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/GIM.0b013e3181993175","volume":"11","author":"NA Kasparian","year":"2009","unstructured":"Kasparian NA et al (2009) Genetic testing for melanoma risk: a prospective cohort study of uptake and outcomes among Australian families. Genet Med 11(4):265\u2013278","journal-title":"Genet Med"},{"issue":"11","key":"209_CR14","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/gim.2014.37","volume":"16","author":"LG Aspinwall","year":"2014","unstructured":"Aspinwall LG et al (2014) Unaffected family members report improvements in daily routine sun protection 2 years following melanoma genetic testing. Genet Med 16(11):846\u2013853","journal-title":"Genet Med"},{"issue":"5","key":"209_CR15","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1007\/s10865-015-9648-z","volume":"38","author":"JM Taber","year":"2015","unstructured":"Taber JM et al (2015) Genetic test reporting enhances understanding of risk information and acceptance of prevention recommendations compared to family history-based counseling alone. J Behav Med 38(5):740\u2013753","journal-title":"J Behav Med"},{"key":"209_CR16","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.canep.2019.05.002","volume":"61","author":"RL Morton","year":"2019","unstructured":"Morton RL et al (2019) Risk attitudes and sun protection behaviour: Can behaviour be altered by using a melanoma genomic risk intervention? Cancer Epidemiol 61:8\u201313","journal-title":"Cancer Epidemiol"},{"issue":"6","key":"209_CR17","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1136\/jmg.2005.032441","volume":"43","author":"KB Niendorf","year":"2006","unstructured":"Niendorf KB et al (2006) MELPREDICT: a logistic regression model to estimate CDKN2A carrier probability. J Med Genet 43(6):501\u2013506","journal-title":"J Med Genet"},{"issue":"2","key":"209_CR18","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1158\/0008-5472.CAN-09-2653","volume":"70","author":"W Wang","year":"2010","unstructured":"Wang W et al (2010) Estimating CDKN2A carrier probability and personalizing cancer risk assessments in hereditary melanoma using MelaPRO. Cancer Res 70(2):552\u2013559","journal-title":"Cancer Res"},{"issue":"10","key":"209_CR19","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1136\/jmedgenet-2017-105205","volume":"55","author":"TP Potjer","year":"2018","unstructured":"Potjer TP et al (2018) CM-Score: a validated scoring system to predict CDKN2A germline mutations in melanoma families from Northern Europe. J Med Genet 55(10):661\u2013668","journal-title":"J Med Genet"},{"issue":"2","key":"209_CR20","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jaad.2019.01.079","volume":"81","author":"NJ Taylor","year":"2019","unstructured":"Taylor NJ et al (2019) Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT. J Am Acad Dermatol 81(2):386\u2013394","journal-title":"J Am Acad Dermatol"},{"key":"209_CR21","unstructured":"eviQ:https:\/\/www.eviq.org.au."},{"key":"209_CR22","unstructured":"eviQ:https:\/\/www.eviq.org.au\/cancer-genetics\/adult\/genetic-testing-for-heritable-pathogenic-variants\/1864-cdkn2a-genetic-testing#, 2020."},{"issue":"2","key":"209_CR23","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1375\/twin.11.2.183","volume":"11","author":"AJ Baxter","year":"2008","unstructured":"Baxter AJ et al (2008) The Queensland Study of Melanoma: Environmental and Genetic Associations (Q-MEGA); study design, baseline characteristics, and repeatability of phenotype and sun exposure measures. Twin Res Hum Genet 11(2):183\u2013196","journal-title":"Twin Res Hum Genet"},{"issue":"9","key":"209_CR24","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.ejca.2008.03.005","volume":"44","author":"M Harland","year":"2008","unstructured":"Harland M et al (2008) A comparison of CDKN2A mutation detection within the melanoma genetics consortium (GenoMEL). Eur J Cancer 44(9):1269\u20131274","journal-title":"Eur J Cancer"},{"issue":"5","key":"209_CR25","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.jid.2016.01.009","volume":"136","author":"NJ Taylor","year":"2016","unstructured":"Taylor NJ et al (2016) Phenotypic and histopathological tumor characteristics according to CDKN2A mutation status among affected members of melanoma families. J Invest Dermatol 136(5):1066\u20131069","journal-title":"J Invest Dermatol"},{"issue":"8","key":"209_CR26","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1002\/humu.21504","volume":"32","author":"PJ Miller","year":"2011","unstructured":"Miller PJ et al (2011) Classifying variants of CDKN2A using computational and laboratory studies. Hum Mutat 32(8):900\u2013911","journal-title":"Hum Mutat"},{"issue":"1","key":"209_CR27","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/0969141313517497","volume":"21","author":"NJ Wald","year":"2014","unstructured":"Wald NJ, Bestwick JP (2014) Is the area under an ROC curve a valid measure of the performance of a screening or diagnostic test? J Med Screen 21(1):51\u201356","journal-title":"J Med Screen"},{"issue":"1","key":"209_CR28","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/EDE.0b013e3181c30fb2","volume":"21","author":"EW Steyerberg","year":"2010","unstructured":"Steyerberg EW et al (2010) Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology 21(1):128\u2013138","journal-title":"Epidemiology"},{"issue":"1","key":"209_CR29","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s10555-017-9661-5","volume":"36","author":"SA Leachman","year":"2017","unstructured":"Leachman SA et al (2017) Identification, genetic testing, and management of hereditary melanoma. Cancer Metastasis Rev 36(1):77\u201390","journal-title":"Cancer Metastasis Rev"},{"issue":"20","key":"209_CR30","doi-asserted-by":"publisher","first-page":"9818","DOI":"10.1158\/0008-5472.CAN-06-0494","volume":"66","author":"AM Goldstein","year":"2006","unstructured":"Goldstein AM et al (2006) High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 66(20):9818\u20139828","journal-title":"Cancer Res"},{"issue":"3","key":"209_CR31","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jaad.2015.08.038","volume":"74","author":"E Soura","year":"2016","unstructured":"Soura E et al (2016) Hereditary melanoma: update on syndromes and management: emerging melanoma cancer complexes and genetic counseling. J Am Acad Dermatol 74(3):395\u2013407","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"209_CR32","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1136\/jmedgenet-2016-104402","volume":"54","author":"F Jouenne","year":"2017","unstructured":"Jouenne F et al (2017) Germline CDKN2A\/P16INK4A mutations contribute to genetic determinism of sarcoma. J Med Genet 54(9):607\u2013612","journal-title":"J Med Genet"},{"issue":"12","key":"209_CR33","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/jnci\/djs221","volume":"104","author":"B Mukherjee","year":"2012","unstructured":"Mukherjee B et al (2012) Risk of non-melanoma cancers in first-degree relatives of CDKN2A mutation carriers. J Natl Cancer Inst 104(12):953\u2013956","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"209_CR34","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3322\/caac.21409","volume":"67","author":"JE Gershenwald","year":"2017","unstructured":"Gershenwald JE et al (2017) Melanoma staging: evidence-based changes in the American joint committee on cancer eighth edition cancer staging manual. CA Cancer J Clin 67(6):472\u2013492","journal-title":"CA Cancer J Clin"},{"key":"209_CR35","unstructured":"Indicators, N.C.C., National cancer control indicators: National cancer stage at diagnosis data. 2018, Cancer Australia."},{"issue":"6","key":"209_CR36","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1158\/1055-9965.EPI-08-0010","volume":"17","author":"LG Aspinwall","year":"2008","unstructured":"Aspinwall LG et al (2008) CDKN2A\/p16 genetic test reporting improves early detection intentions and practices in high-risk melanoma families. Cancer Epidemiol Biomarkers Prev 17(6):1510\u20131519","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"11","key":"209_CR37","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/jnci\/djw135","volume":"108","author":"H Helgadottir","year":"2016","unstructured":"Helgadottir H et al (2016) Germline CDKN2A mutation status and survival in familial melanoma cases. J Natl Cancer Inst 108(11):135","journal-title":"J Natl Cancer Inst"},{"key":"209_CR38","unstructured":"Mann, G., A\/Prof Anne Cust, Damian, D, Paul Fishburn, Kelly, J, Victoria Mar MBBS, FACD, PhD, Soyer, P, Cancer council Australia melanoma guidelines working party. What interventions have been shown to reduce the risk of death from melanoma in those assessed to be at high risk of new primary melanoma? https:\/\/wiki.cancer.org.au\/australiawiki\/index.php?oldid=186156, Accessed Feb 28, 2020. Available from https:\/\/wiki.cancer.org.au\/australia\/Clinical_question:What_interventions_reduce_risk_of_death_from_melanoma_in_high_risk_people%3F. In: Cancer Council Australia Melanoma Guidelines Working Party. Clinical practice guidelines for the diagnosis and management of melanoma. Sydney: Cancer Council Australia. https:\/\/wiki.cancer.org.au\/australia\/Guidelines:Melanoma."},{"key":"209_CR39","unstructured":"https:\/\/wiki.cancer.org.au\/australiawiki\/index.php?oldid=209426, Accessed Feb 28, 2020. Available from: https:\/\/wiki.cancer.org.au\/australia\/Guidelines:Melanoma.."}],"container-title":["Familial Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-020-00209-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10689-020-00209-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-020-00209-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T23:52:55Z","timestamp":1632873175000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10689-020-00209-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,29]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["209"],"URL":"https:\/\/doi.org\/10.1007\/s10689-020-00209-x","relation":{},"ISSN":["1389-9600","1573-7292"],"issn-type":[{"value":"1389-9600","type":"print"},{"value":"1573-7292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,29]]},"assertion":[{"value":"29 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have all declared that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Human Research Ethics Committees Sydney: HREC\/13\/CIPHS\/71, Queensland: HREC\/14\/QPAH\/495","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}